Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Romidepsin in Japanese patients with relapsed or refractory peripheral T-cell lymphoma: a phase I/II and pharmacokinetics study
Dai Maruyama, Kensei Tobinai, Michinori Ogura, et al.
International Journal of Hematology (2017) Vol. 106, Iss. 5, pp. 655-665
Closed Access | Times Cited: 35

Showing 1-25 of 35 citing articles:

Small Molecules Targeting HATs, HDACs, and BRDs in Cancer Therapy
Donglu Wu, Ye Qiu, Yunshuang Jiao, et al.
Frontiers in Oncology (2020) Vol. 10
Open Access | Times Cited: 62
Optimal therapeutic targeting by HDAC inhibition in biopsy-derived treatment-naïve diffuse midline glioma models
Nicholas A. Vitanza, Matthew C. Biery, Carrie Myers, et al.
Neuro-Oncology (2020) Vol. 23, Iss. 3, pp. 376-386
Open Access | Times Cited: 57
Oral histone deacetylase inhibitor tucidinostat (HBI‐8000) in patients with relapsed or refractory adult T‐cell leukemia/lymphoma: Phase IIb results
Atae Utsunomiya, Koji Izutsu, Tatsuro Jo, et al.
Cancer Science (2022) Vol. 113, Iss. 8, pp. 2778-2787
Open Access | Times Cited: 34
Oral HDAC inhibitor tucidinostat in patients with relapsed or refractory peripheral T-cell lymphoma: phase IIb results
Shinya Rai, Won Seog Kim, Kiyoshi Ando, et al.
Haematologica (2022) Vol. 108, Iss. 3, pp. 811-821
Open Access | Times Cited: 32
The Role of Epigenetic Modifications in Systemic Sclerosis: A Druggable Target
John Henderson, J.H.W. Distler, Steven O’Reilly
Trends in Molecular Medicine (2019) Vol. 25, Iss. 5, pp. 395-411
Closed Access | Times Cited: 45
Therapeutic applications and biological activities of bacterial bioactive extracts
Zainab Abdelghani, Nancy Hourani, Zahraa Zaidan, et al.
Archives of Microbiology (2021) Vol. 203, Iss. 8, pp. 4755-4776
Open Access | Times Cited: 38
Update on histone deacetylase inhibitors in peripheral T-cell lymphoma (PTCL)
Guang Lu, Shikai Jin, Su-Wen Lin, et al.
Clinical Epigenetics (2023) Vol. 15, Iss. 1
Open Access | Times Cited: 13
Forodesine in the treatment of relapsed/refractory peripheral T-cell lymphoma: an evidence-based review
Shinichi Makita, Akiko Miyagi Maeshima, Dai Maruyama, et al.
OncoTargets and Therapy (2018) Vol. Volume 11, pp. 2287-2293
Open Access | Times Cited: 34
Synergistic antitumor effect of histone deacetylase class IIa inhibitor with lenvatinib in hepatocellular carcinoma
Ryo Ito, Koji Miyanishi, Tomohiro Kubo, et al.
Hepatology International (2023) Vol. 17, Iss. 3, pp. 735-744
Closed Access | Times Cited: 10
The Status and Prospects of Epigenetics in the Treatment of Lymphoma
Jiaxin Liu, Jianan Li, Hongyu Wu, et al.
Frontiers in Oncology (2022) Vol. 12
Open Access | Times Cited: 13
Improving gastrointestinal quality of life: romidepsin to tucidinostat in a case of angioimmunoblastic T cell lymphoma
Atsushi Isoda, Yukie Terasaki, Shuhei Kanaya, et al.
BMJ Case Reports (2024) Vol. 17, Iss. 1, pp. e256315-e256315
Closed Access | Times Cited: 2
Biology and Molecular Pathogenesis of Mature T-Cell Lymphomas
José R. Cortés, Teresa Palomero
Cold Spring Harbor Perspectives in Medicine (2020) Vol. 11, Iss. 5, pp. a035402-a035402
Open Access | Times Cited: 15
Oral histone deacetylase inhibitor HBI-8000 (tucidinostat) in Japanese patients with relapsed or refractory non-Hodgkin’s lymphoma: phase I safety and efficacy
Makoto Yoshimitsu, Kiyoshi Ando, Takashi Ishida, et al.
Japanese Journal of Clinical Oncology (2022)
Open Access | Times Cited: 8
Risk factors and timing of autologous stem cell transplantation for patients with peripheral T-cell lymphoma
Satoshi Yamasaki, Dai Chihara, Sung Won Kim, et al.
International Journal of Hematology (2018) Vol. 109, Iss. 2, pp. 175-186
Closed Access | Times Cited: 12
Targeting epigenetic regulators in the treatment of T-cell lymphoma
Nada Ahmed, Andrew L. Feldman
Expert Review of Hematology (2020) Vol. 13, Iss. 2, pp. 127-139
Open Access | Times Cited: 10
Effects of stem cell transplantation in patients with peripheral T-cell lymphoma not otherwise specified and angioimmunoblastic T-cell lymphoma
Satoshi Yamasaki, Shuro Yoshida, Koji Kato, et al.
International Journal of Hematology (2020) Vol. 112, Iss. 1, pp. 74-83
Closed Access | Times Cited: 9
Characterization of Regulatory and Transporter Genes in the Biosynthesis of Anti-Tuberculosis Ilamycins and Production in a Heterologous Host
Jianqiao He, Wei Xin, Zhijie Yang, et al.
Marine Drugs (2020) Vol. 18, Iss. 4, pp. 216-216
Open Access | Times Cited: 9
Nodal peripheral T-cell lymphoma: Chemotherapy-free management, are we there yet?
Sharina Macapagal, N. Nora Bennani
Blood Reviews (2023) Vol. 60, pp. 101071-101071
Closed Access | Times Cited: 3
Efficacy and safety of histone deacetylase inhibitors in peripheral T-cell lymphoma: a systematic review and meta-analysis on prospective clinical trials
Peipei Yang, Yali Tao, Ailin Zhao, et al.
Frontiers in Oncology (2023) Vol. 13
Open Access | Times Cited: 3
Efficacy and Treatment-Related Adverse Events of Romidepsin in PTCL Clinical Studies: A Systematic Review and Meta-Analysis
Jun Du, Xinle Han, Su-Wen Lin, et al.
Frontiers in Medicine (2021) Vol. 8
Open Access | Times Cited: 7
Precise diagnosis and targeted therapy of nodal T-follicular helper cell lymphoma (T-FHCL)
Jun Du, Shikai Jin, Minghui Zhang, et al.
Frontiers in Oncology (2023) Vol. 13
Open Access | Times Cited: 2
Japanese subgroup analysis in the Asian phase II study of darinaparsin in patients with relapsed or refractory peripheral T-cell lymphoma
Eiju Negoro, Takahiro Yamauchi, Noriko Fukuhara, et al.
Journal of Clinical and Experimental Hematopathology (2023) Vol. 63, Iss. 2, pp. 108-120
Open Access | Times Cited: 2
Recent advances in understanding and managing T-cell lymphoma
Jun Ho Yi, Seok Jin Kim, Won Seog Kim
F1000Research (2017) Vol. 6, pp. 2123-2123
Open Access | Times Cited: 4
Comparison of prognostic scores in transplant-ineligible patients with peripheral T-cell lymphoma not otherwise specified and angioimmunoblastic T-cell lymphoma: a retrospective study from the national hospital organization in Japan
Satoshi Yamasaki, Hiroatsu Iida, Isao Yoshida, et al.
Leukemia & lymphoma/Leukemia and lymphoma (2020) Vol. 62, Iss. 4, pp. 819-827
Closed Access | Times Cited: 4
Establishment and characterization of two novel patient-derived myxoid liposarcoma cell lines
Rei Noguchi, Yuki Yoshimatsu, Yooksil Sin, et al.
Human Cell (2022) Vol. 35, Iss. 4, pp. 1279-1289
Closed Access | Times Cited: 3
Page 1 - Next Page

Scroll to top